Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TARBP2 | Q15633 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464044 | 0.82 | C3AR1 (0.36) | BMP1C3AR1FBP1 | |
| SCHEMBL568902 | 0.81 | C3AR1 (0.36) | BMP1C3AR1FBP1ALDH1A1 | |
| SCHEMBL568551 | 0.76 | CTSK (0.39) | BMP1C3AR1FBP1 | |
| SCHEMBL8514003 | 0.76 | C3AR1 (0.33) | POLBC3AR1 | |
| SCHEMBL3466936 | 0.75 | HDAC4 (0.34) | BMP1C3AR1 | |
| SCHEMBL13689212 | 0.75 | BMP1 (0.41) | BMP1POLBIKBKBC3AR1L3MBTL1 | |
| SCHEMBL3742227 | 0.71 | POLB (0.44) | BMP1POLBIKBKBFBP1L3MBTL1 | |
| SCHEMBL21976902 | 0.68 | PPARG (0.30) | — | |
| SCHEMBL3465662 | 0.68 | ALDH1A1 (0.41) | BMP1C3AR1ALDH1A1 | |
| SCHEMBL21639134 | 0.68 | ATM (0.43) | IKBKBC3AR1TARBP2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | BMP1 2461/4885POLB 2974/4885IKBKB 966/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | BMP1 1928/4885POLB 1195/4885IKBKB 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.